While acute IL-1 responses can be mitigated with IL-1 antagonists, such as IL-1RA, to maintain or restore androgen and AR dependence and sensitivity to ADT and anti-androgens in PCa cells, chronic IL-1-induced phenotypes are not reversible and, therefore, require the identification of alternative therapeutic targets (Fig 7). This evidence concerns the gene IL1B and posterior cortical atrophy.